- 1998
Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern,
Br J Pharmacol, vol. 125, no. 5, pp. 997-1004. DOI
Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 159-68.
Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease,
Clin Neuropharmacol, vol. 21, no. 3, pp. 152-8.
Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol,
Pharm Res, vol. 15, no. 3, pp. 442-8.
Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor,
J Pharmacol Exp Ther, vol. 284, no. 3, pp. 1095-103.
Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats,
Br J Pharmacol, vol. 124, no. 3, pp. 607-18. DOI
Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine,
J Pharmacol Exp Ther, vol. 286, no. 1, pp. 142-9.
Validation and testing of a new iontophoretic continuous flow through transport cell,
J Control Release, vol. 51, no. 1, pp. 85-91. DOI
Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam,
J Pharmacol Exp Ther, vol. 284, no. 1, pp. 202-7.
Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials,
J Pharmacol Toxicol Methods, vol. 39, no. 1, pp. 19-27. DOI
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats,
J Pharmacol Exp Ther, vol. 284, no. 2, pp. 460-6.
Effects of repeated seizure induction on seizure activity, post-ictal and interictal behavior,
Brain Res, vol. 814, no. 1-2, pp. 199-208. DOI
Modelling of the pharmacodynamic interaction between phenytoin and sodium valproate,
Br J Pharmacol, vol. 125, no. 7, pp. 1610-6. DOI
Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation,
Br J Pharmacol, vol. 124, no. 7, pp. 1534-40. DOI
Phamacokinetic-pharmacodynamic modelling of behavioural responses,
Neurosci Biobehav Rev, vol. 23, no. 2, pp. 229-36. DOI
- 1997
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier,
Brain Res Brain Res Rev, vol. 25, no. 1, pp. 27-49. DOI
A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population,
Br J Clin Pharmacol, vol. 44, no. 3, pp. 267-75.
Seizure patterns in kindling and cortical stimulation models of experimental epilepsy,
Brain Res, vol. 770, no. 1-2, pp. 221-7. DOI
Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling,
Int J Clin Pharmacol Ther, vol. 35, no. 10, pp. 442-6.
On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation,
J Pharmacol Toxicol Methods, vol. 38, no. 2, pp. 81-5. DOI
Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats,
J Pharmacol Toxicol Methods, vol. 38, no. 2, pp. 99-108. DOI
Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep,
Clin Pharmacol Ther, vol. 62, no. 4, pp. 444-52. DOI
Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats,
Br J Pharmacol, vol. 122, no. 3, pp. 525-33. DOI
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease,
J Chromatogr B Biomed Sci Appl, vol. 702, no. 1-2, pp. 131-41.
8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo,
J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.


